Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
CAPSULE
**DOSAGE AND ADMINISTRATION** Cloxacillin should not be used orally for the initial treatment of severe life-threatening infections, but may be used as a follow-up therapy after parenteral penicillinase-resistant penicillin therapy. **Adult dose** Oral, 250 to 500 mg every six hours; or as directed. **Paediatric dose** Infants and children up to 20 kg of body weight: Oral 12.5 to 25 mg per kg of body weight every six hours; or as directed. Children 20 kg of body weight and over - See adult dose. Note: The information given here is limited. For further information, consult your doctor or pharmacist.
ORAL
Medical Information
**INDICATIONS** For treatment of: - Infections caused by penicillinase-producing staphylococci - Respiratory tract infections - Skin and soft-tissue infections - Disseminated infections caused by pneumococci, group A beta-hemolytic streptococci and penicillin G-resistant and penicillin G-sensitive staphylococci
**CONTRAINDICATIONS** Avoid in patients known to be hypersensitive to penicillins.
J01CF02
cloxacillin
Manufacturer Information
GOLDPLUS UNIVERSAL PTE LTD
HOVID BHD
Active Ingredients
Documents
Package Inserts
Cloxacap Capsule PI.pdf
Approved: November 8, 2022